keyword
MENU ▼
Read by QxMD icon Read
search

SCLC

keyword
https://www.readbyqxmd.com/read/28212995/heterogeneity-of-circulating-tumor-cells-ctcs-in-patients-with-recurrent-small-cell-lung-cancer-sclc-treated-with-pazopanib
#1
I Messaritakis, E Politaki, M Plataki, V Karavassilis, N Kentepozidis, F Koinis, E Samantas, V Georgoulias, A Kotsakis
OBJECTIVES: To investigate the effect of pazopanib on different CTCs subpopulations in patients with recurrent SCLC and evaluate their clinical relevance. METHODS: Peripheral blood was obtained before the administration of pazopanib (n=56 patients), after the first cycle (n=35 patients) and at disease progression (n=45 patients). CTCs were detected by CellSearch and double immunofluorescent staining using antibodies against the cytokeratins (CK), TTF-1, CD56 and VEGFR2...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28212994/an-open-label-phase-ii-study-of-the-polo-like-kinase-1-plk-1-inhibitor-bi-2536-in-patients-with-relapsed-small-cell-lung-cancer-sclc
#2
Mark M Awad, Quincy S-C Chu, Leena Gandhi, Joe J Stephenson, Ramaswamy Govindan, Daniel S Bradford, Philip D Bonomi, David M Ellison, Keith D Eaton, Holger Fritsch, Gerd Munzert, Bruce E Johnson, Mark A Socinski
OBJECTIVES: This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed small cell lung cancer (SCLC). Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response, and safety. MATERIALS AND METHODS: Patients were treated with the recommended phase II dose of 200mg of BI 2536 intravenously every 21days. This was a two-stage design with an early stopping rule in place if responses were not seen in at least 2 of the first 18 enrolled patients...
February 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28212573/dynamic-variations-in-epithelial-to-mesenchymal-transition-emt-atm-and-slfn11-govern-response-to-parp-inhibitors-and-cisplatin-in-small-cell-lung-cancer
#3
C Allison Stewart, Pan Tong, Robert J Cardnell, Triparna Sen, Lerong Li, Carl M Gay, Fatemah Masrorpour, You Fan, Rasha O Bara, Ying Feng, Yuanbin Ru, Junya Fujimoto, Samrat T Kundu, Leonard E Post, Karen Yu, Yuqiao Shen, Bonnie S Glisson, Ignatio Wistuba, John V Heymach, Don L Gibbons, Jing Wang, Lauren Averett Byers
Small cell lung cancer (SCLC) is one of the most aggressive forms of cancer, with a 5-year survival <7%. A major barrier to progress is the absence of predictive biomarkers for chemotherapy and novel targeted agents such as PARP inhibitors. Using a high-throughput, integrated proteomic, transcriptomic, and genomic analysis of SCLC patient-derived xenografts (PDXs) and profiled cell lines, we identified biomarkers of drug sensitivity and determined their prevalence in patient tumors. In contrast to breast and ovarian cancer, PARP inhibitor response was not associated with mutations in homologous recombination (HR) genes (e...
February 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28204981/phase-1b-trial-of-proteasome-inhibitor-carfilzomib-with-irinotecan-in-lung-cancer-and-other-irinotecan-sensitive-malignancies-that-have-progressed-on-prior-therapy-onyx-ist-reference-number-car-ist-553
#4
Susanne M Arnold, Kari Chansky, Markos Leggas, Michael A Thompson, John L Villano, John Hamm, Rachel E Sanborn, Glen J Weiss, Gurkamal Chatta, Maria Q Baggstrom
Introduction Proteasome inhibition is an established therapy for many malignancies. Carfilzomib, a novel proteasome inhibitor, was combined with irinotecan to provide a synergistic approach in relapsed, irinotecan-sensitive cancers. Materials and Methods Patients with relapsed irinotecan-sensitive cancers received carfilzomib (Day 1, 2, 8, 9, 15, and 16) at three dose levels (20/27 mg/m2, 20/36 mg/m2 and 20/45 mg/m2/day) in combination with irinotecan (Days 1, 8 and 15) at 125 mg/m2/day. Key eligibility criteria included measurable disease, a Zubrod PS of 0 or 1, and acceptable organ function...
February 16, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28203418/clinical-outcomes-of-surgically-resected-combined-small-cell-lung-cancer-a-two-institutional-experience
#5
Chao Zhang, Haitang Yang, Heng Zhao, Baoping Lang, Xiangdong Yu, Peng Xiao, Xiao Zhang
BACKGROUND: The combined small cell lung cancer (c-SCLC) was rare and its clinicopathological characteristics had not been thoroughly described. The aim of this study was to determine prognostic factors and survival in c-SCLC patients. METHODS: Clinical records of patients with c-SCLC who underwent surgery between January 2009 and December 2013 in two institutions were retrospectively reviewed. RESULTS: Ninety-seven patients were identified...
January 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28202905/risk-factors-for-brain-metastases-after-prophylactic-cranial-irradiation-in-small-cell-lung-cancer
#6
Haiyan Zeng, Peng Xie, Xue Meng, Shuanghu Yuan, Xindong Sun, Wanlong Li, Bingjie Fan, Xiaolin Li, Jinming Yu
Despite administration of prophylactic cranial irradiation (PCI), some small cell lung cancer (SCLC) patients still suffer from brain metastases (BM) with unknown risk factors. We conducted this study to identify patients with higher BM risk after PCI and improve their outcome. The characteristics and survival of all the SCLC patients underwent PCI in our institute from 2003 to 2014 were analyzed. Kaplan-Meier method was applied to estimate BM free survival (BMFS) and overall survival (OS). Cox regression analyses were performed to explore risk factors for BM...
February 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28196592/awakening-of-schlafen11-to-tackle-chemotherapy-resistance-in-sclc
#7
Katrien Berns, Anton Berns
Chemotherapy resistance arises invariably in small cell lung cancer (SCLC). In this issue of Cancer Cell, Gardner et al. find that in some SCLC, EZH2 mediates resistance via downregulation of Schlafen11 (SLFN11). Combining EZH2 inhibition with chemotherapy effectively overcomes drug resistance of xenografted SCLC, holding promise for new treatment paradigms.
February 13, 2017: Cancer Cell
https://www.readbyqxmd.com/read/28193529/heterogeneity-in-immune-marker-expression-after-acquisition-of-resistance-to-egfr-kinase-inhibitors-analysis-of-a-case-with-small-cell-lung-cancer-transformation
#8
Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Kim Ellison, Christopher J Rivard, Tetsuya Mitsudomi, Fred R Hirsch
INTRODUCTION: Expression of immune-markers is of scientific interest due to their potential roles as predictive biomarkers for immunotherapy. Although the microenvironment of metastatic tumors and/or therapy-inducible histological transformation may affect the expression of these immune-markers, there is little data regarding this context. METHODS: A 76-year-old never-smoking female with epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma (AC) acquired resistance to gefitinib...
February 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28192473/potential-effect-of-spliceosome-inhibition-in-small-cell-lung-cancer-irrespective-of-the-myc-status
#9
Kenichi Suda, Leslie Rozeboom, Hui Yu, Kim Ellison, Christopher J Rivard, Tetsuya Mitsudomi, Fred R Hirsch
Small cell lung cancer (SCLC) is a highly aggressive malignancy with few therapeutic advances in the treatment in recent decades. Based on a recent study that identified the spliceosome as a therapeutic vulnerability in MYC-driven breast cancers, we evaluated the efficacy of a spliceosome inhibitor in SCLC cell lines and analyzed the correlation with MYC status. Among 23 SCLC cell lines examined, eight showed high MYC protein expression (> 80% positive cells) by immunohistochemistry (IHC), while 10 cell lines demonstrated no staining for MYC...
2017: PloS One
https://www.readbyqxmd.com/read/28184379/establishment-of-patient-derived-xenografts-in-mice
#10
Dongkyoo Park, Dongsheng Wang, Guo Chen, Xingming Deng
Patient-derived xenograft (PDX) models for cancer research have recently attracted considerable attention in both the academy and industry (Hidalgo et al., 2014; Wilding and Bodmer, 2014). PDX models have been developed from different tumor types including lung cancer to improve the drug development process. These models are used for pre-clinical drug evaluation and can be used for the predictive results of clinical outcomes because they conserve original tumor characteristics such as heterogeneity, complexity and molecular diversity (Kopetz et al...
November 20, 2016: Bio-protocol
https://www.readbyqxmd.com/read/28179346/radiological-features-of-the-surgically-resected-small-sized-small-cell-lung-cancer-on-computed-tomography
#11
Gouji Toyokawa, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Shinkichi Takamori, Takaki Akamine, Kazuki Takada, Masakazu Katsura, Fumihiro Shoji, Tatsuro Okamoto, Yoshihiko Maehara
BACKGROUND/AIM: Surgical resection can be applied in cases of early-stage small-cell lung cancer (SCLC). Predicting the histology of SCLC and discriminating SCLC from other histologies would be useful for determining the optimal treatment strategies for small pulmonary nodules that have not been preoperatively diagnosed. MATERIALS AND METHODS: The study population included 17 patients with resected SCLC and 296 patients with adenocarcinoma (ADC) whose preoperative CT were available...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28164590/human-epididymis-protein-4-he4-in-patients-with-small-cell-lung-cancer
#12
Ewa Wojcik, Jadwiga Tarapacz, Urszula Rychlik, Zofia Stasik, Beata Sas-Korczynska, Piotr Skotnicki, Jan K Kulpa
BACKGROUND: The aim of the present study was to compare the diagnostic utility of HE4 with NSE, ProGRP, CYFRA 21-1, CEA, and CA 125 and evaluate their prognostic value in patients with small-cell lung cancer (SCLC). METHODS: HE4, ProGRP, NSE, CYFRA 21-1, CEA, and CA 125 assays were performed in 63 patients with smallcell lung cancer (limited disease (LD) - 41, extensive disease (ED) - 22) and in 66 individuals of the reference group. RESULTS: Area under the ROC curves for HE4, ProGRP, NSE, CA 125, CYFRA 21-1, and CEA were 0...
September 1, 2016: Clinical Laboratory
https://www.readbyqxmd.com/read/28154994/neutrophil-to-lymphocyte-ratio-predicts-outcome-in-limited-disease-small-cell-lung-cancer
#13
Lukas Käsmann, Louisa Bolm, Steven E Schild, Stefan Janssen, Dirk Rades
INTRODUCTION: Patients with limited disease small-cell lung cancer (SCLC) receive radiochemotherapy followed by prophylactic cranial irradiation. The prognosis of these patients remains poor with a median survival of 16-24 months. Systemic inflammation was suggested as an important prognostic factor for outcomes. This study investigated the impact of systemic inflammation measured with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at first diagnosis in patients with limited disease SCLC for outcomes...
February 2, 2017: Lung
https://www.readbyqxmd.com/read/28152979/the-important-role-of-circulating-cyfra21-1-in-metastasis-diagnosis-and-prognostic-value-compared-with-carcinoembryonic-antigen-and-neuron-specific-enolase-in-lung-cancer-patients
#14
Li Zhang, Dan Liu, Lei Li, Dan Pu, Ping Zhou, Yuting Jing, He Yu, Yanwen Wang, Yihan Zhu, Yanqi He, Yalun Li, Shuang Zhao, Zhixin Qiu, Weimin Li
BACKGROUND: The roles of carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21-1) and neuron-specific enolase (NSE) in metastases occurrence and poor diagnosis in specific histological classifications of lung cancer need further exploring. In this study, we investigated relationship between elevated levels of three biomarkers of CEA, CYFRA21-1 and NSE (individually and in combination) and metastasis, survival status and prognosis in lung cancer patients. METHODS: Eight hundred and sixty eight lung cancer patients including adenocarcinoma (ADC, N = 445), squamous cell carcinoma (SCC, N = 215), small cell lung cancer (SCLC, N = 159) and other types (N = 49) were categorized into negative, moderate and high groups according to serum levels of biomarkers, and were then categorized into negative, single, double and triple groups according to any positive combination of three biomarkers...
February 2, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28152514/high-pd-l1-expression-is-associated-with-stage-iv-disease-and-poorer-overall-survival-in-186-cases-of-small-cell-lung-cancers
#15
Yih-Leong Chang, Ching-Yao Yang, Yen-Lin Huang, Chen-Tu Wu, Pan-Chyr Yang
BACKGROUND: Small cell lung cancer (SCLC) is an aggressive malignancy with a distinct natural history and dismal prognosis. SCLC is characterized as a recalcitrant neoplasm with limited therapeutic options and platinum-based chemotherapy is the treatment of choice. Programmed cell death-ligand 1(PD-L1)-mediated immune escape may be a suitable target for specific therapy, but its role in SCLC is unclear. MATERIALS AND METHODS: In total, 186 SCLC cases were investigated...
February 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28151731/electronic-edge-state-and-space-charge-phenomena-in-long-gan-nanowires-and-nanoribbons
#16
Viktor Sydoruk, Ihor Zadorozhnyi, Hilde Hardtdegen, Hans Lueth, Michail Petrychuk, A Naumov, Vadym Korotyeyev, Kochelap A, A Belyaev, Svetlana Vitusevich
We studied space charge distribution phenomena in planar GaN nanowires and nanoribbons (NRs). The results obtained at low voltages demonstrate that the electron concentration changes not only at the edges of the nanoribbon, but also in the middle part of the nanoribbon. The effect is stronger with decreasing nanoribbon width. Moreover, the spatial separation of the positive and negative charges results in electric field patterns outside the nanoribbon. This remarkable feature of electrostatic fields outside the NRs may be even stronger in 2D material structures...
February 2, 2017: Nanotechnology
https://www.readbyqxmd.com/read/28149765/a-rare-case-of-palatin-tonsillar-metastasis-from-small-cell-lung-cancer
#17
Chiara D'Antonio, Alberto Lombardini, Concetta Elisa Onesti, Rosa Falcone, Adriana Romiti, Marianna Lombardi, Salvatore Lauro, Paolo Marchetti
Tonsillar metastases are absolutely rare. Small cell lung cancer (SCLC) is known to be the most frequent histological type of tonsillar metastases, however the way of tumor cells spreading to tonsil remains controversial. We described a case report of 76-year-old man with SCLC and tonsillar metastases, to highlight the importance of oral cavity evaluation as a part of a clinical exam and to show the rare tumor cells spreading.
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149764/third-generation-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-in-t790m-positive-non-small-cell-lung-cancer-review-on-emerged-mechanisms-of-resistance
#18
REVIEW
Roberta Minari, Paola Bordi, Marcello Tiseo
Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. Although exciting survival data and response rates have been registered in patients treated with this and other third-generation EGFR-TKIs, unfortunately acquired resistance still occurs after approximately 10 months...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28138259/advances-in-antiangiogenic-treatment-of-small-cell-lung-cancer
#19
REVIEW
Hongyang Lu, Zhiming Jiang
Small-cell lung cancer (SCLC), a poorly differentiated neuroendocrine malignancy, has a rapid growth rate, strong aggressiveness, early metastases, and poor prognosis. Angiogenesis greatly contributes to the metastatic process of SCLC, which has a higher vascularization compared with non-small-cell lung cancer (NSCLC). SCLC might constitute an ideal malignancy for assessing new antiangiogenic drugs and therapeutic strategies. Combining bevacizumab with paclitaxel has therapeutic benefits in chemoresistant, relapsed SCLC...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28135143/italian-multicenter-phase-iii-randomized-study-of-cisplatin-plus-etoposide-with-or-without-bevacizumab-as-first-line-treatment-in-extensive-disease-small-cell-lung-cancer-the-goirc-aifa-farm6pmfjm-trial
#20
Marcello Tiseo, Luca Boni, Francesca Ambrosio, Andrea Camerini, Editta Baldini, Saverio Cinieri, Matteo Brighenti, Francesca Zanelli, Efisio Defraia, Rita Chiari, Claudio Dazzi, Carmelo Tibaldi, Gianni Michele Turolla, Vito D'Alessandro, Nicoletta Zilembo, Anna Rita Trolese, Francesco Grossi, Ferdinando Riccardi, Andrea Ardizzoni
Purpose Considering promising results in phase II studies, a randomized phase III trial was designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide for treatment of extensive-disease (ED) small-cell lung cancer (SCLC). Patients and Methods Treatment-naive patients with ED-SCLC were randomly assigned to receive either cisplatin plus etoposide (arm A) or the same regimen with bevacizumab (arm B) for a maximum of six courses. In the absence of progression, patients in arm B continued bevacizumab alone until disease progression or for a maximum of 18 courses...
January 30, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
37726
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"